{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:46:51Z","timestamp":1759366011448,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.acuro.2019.06.007","type":"journal-article","created":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T13:09:18Z","timestamp":1573909758000},"page":"27-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sunitinib versus pazopanib para el tratamiento del carcinoma de c\u00e9lulas renales metast\u00e1sico: experiencia en 2 hospitales turcos"],"prefix":"10.1016","volume":"44","author":[{"given":"M.","family":"Ekenel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Karabulut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Cil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Z\u0131rt\u0131loglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Tural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2019.06.007_bib0085","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/1756287217713902","article-title":"Sunitinib in the treatment of renal cell carcinoma: An update on recent evidence","volume":"9","author":"Rizzo","year":"2017","journal-title":"Ther Adv Urol."},{"key":"10.1016\/j.acuro.2019.06.007_bib0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acuro.2019.06.007_bib0095","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2019.06.007_bib0100","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase iii trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2019.06.007_bib0105","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acuro.2019.06.007_bib0110","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2019.06.007_bib0115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2016.06.016","article-title":"First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"65","author":"Ruiz-Morales","year":"2016","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.acuro.2019.06.007_bib0120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5489\/cuaj.4398","article-title":"First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience","volume":"11","author":"Lalani","year":"2017","journal-title":"Can Urol Assoc J."},{"key":"10.1016\/j.acuro.2019.06.007_bib0125","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ejca.2014.01.025","article-title":"A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma","volume":"50","author":"Najjar","year":"2014","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.acuro.2019.06.007_bib0130","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/annonc\/mdv315","article-title":"Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis","volume":"26","author":"Bracarda","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acuro.2019.06.007_bib0135","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40268-017-0209-5","article-title":"Feasibility, safety, and efficacy of an alternative schedule of sunitinib for the treatment of patients with metastatic renal cell carcinoma: A retrospective study","volume":"17","author":"Buti","year":"2017","journal-title":"Drugs R D."},{"key":"10.1016\/j.acuro.2019.06.007_bib0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-018-0617-1","article-title":"Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial","volume":"11","author":"Guo","year":"2018","journal-title":"J Hematol Oncol."},{"key":"10.1016\/j.acuro.2019.06.007_bib0145","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.ejca.2012.05.022","article-title":"An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer","volume":"48","author":"Powles","year":"2012","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.acuro.2019.06.007_bib0150","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00280-016-3093-8","article-title":"Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features","volume":"78","author":"Kim","year":"2016","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.acuro.2019.06.007_bib0155","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.euf.2016.03.017","article-title":"Pharmacogenomic markers of targeted therapy toxicity in patients with metastatic renal cell carcinoma","volume":"2","author":"De Velasco","year":"2016","journal-title":"Eur Urol Focus."},{"key":"10.1016\/j.acuro.2019.06.007_bib0160","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: Results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480619301482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480619301482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:36:00Z","timestamp":1759322160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480619301482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0210480619301482"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2019.06.007","relation":{},"ISSN":["0210-4806"],"issn-type":[{"type":"print","value":"0210-4806"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sunitinib versus pazopanib para el tratamiento del carcinoma de c\u00e9lulas renales metast\u00e1sico: experiencia en 2 hospitales turcos","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2019.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of AEU.","name":"copyright","label":"Copyright"}]}}